Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
  • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
  • A61K49/0026—Acridine dyes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
  • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
  • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
  • A61K49/0039—Coumarin dyes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
  • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
  • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
  • A61K49/0056—Peptides, proteins, polyamino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/08—Drugs for disorders of the urinary system of the prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/06—Peri-condensed systems

Definitions

• This invention relates generally to novel azo bioconjugates for use in phototherapy.
• NIR visible and near-infrared
• UV-A long-wavelength
• Phototherapy has been demonstrated to be a safe and effective procedure for the treatment of various surface lesions, both external and internal. Its efficacy is comparable to that of radiotherapy, but without the harmful radiotoxicity of critical non-target organs.
• Phototherapy has been in existence for many centuries and has been used to treat various skin surface ailments.
• plant extracts psoralens
• sunlight were used to treat vitiligo.
• Von Tappeiner and Jesionek used eosin as a photosensitizer for the treatment of skin cancer, lupus of the skin, and condylomata of female genitalia.
• Phototherapeutic procedures require photosensitizers (i.e. chromophores) which have high absorptivity. These compounds should preferably be chemically inert, and become activated only upon irradiation with light of an appropriate wavelength. Light-initiated selective tissue injury can be induced when these photosensitizers bind to target tissues, either directly or through attachment to a bioactive carrier. Furthermore, if the photosensitizer is also a chemotherapeutic agent (e.g. anthracycline antitumor agents), then an enhanced therapeutic effect can be attained.
• chemotherapeutic agent e.g. anthracycline antitumor agents
• Effective phototherapeutic agents should have the following properties: (a) large molar extinction coefficient; (b) long triplet lifetime; (c) high yield of singlet oxygen and/or other reactive intermediates, viz., free radicals, nitrenes, carbenes, open-shell ionic species such as cabonium ions and the like; (d) efficient energy or electron transfer to cellular components; (e) low tendency to form aggregation in aqueous milieu; (f) efficient and selective targeting of lesions; (g) rapid clearance from blood and non-target tissues; (h) low systemic toxicity; and (i) lack of mutagenicity. Photosensitizers operate via two distinct pathways, termed
• the type 1 mechanism is shown in the following scheme: l SENSITIZER ⁇ (SENSITIZER)*
• the Type 1 mechanism involves direct energy or electron transfer from the photosensitizer to the cellular components, thereby causing cell death.
• the Type 2 mechanism involves distinct steps as shown in the following scheme: v SENSITIZER ⁇ (SENSITIZER)*
• (f) and (g) are the most general and, of these two alternatives, there is a general consensus that (f) is the most likely mechanism by which the phototherapeutic effect of porphyrin-like compounds is induced.
• Most of the currently known photosensitizers are commonly referred to as PDT agents and operate via the Type 2 mechanism.
• Photofrin II a hematoporphyrin derivative
• Type 1 photosensitizers do not require oxygen for causing cellular injury.
• the Type 1 mechanism involves two steps (photoexcitation and direct energy transfer) whereas the Type 2 mechanism involves three steps (photoexcitation, singlet oxygen generation, and energy transfer).
• some tumors have hypoxic regions that render the Type 2 mechanism ineffective.
• anthracyline antitumor agents e.g. anthracyline antitumor agents.
• the present invention addresses this need and discloses novel azo derivatives and their bioconjugates that absorb in the low-energy, ultraviolet, visible, or near-infrared (NIR) region of the electromagnetic spectrum that are used for the phototherapy of tumors and other lesions. More specifically, the present invention discloses azo compounds having the formula 1
• the present invention also discloses a method of performing a phototherapeutic or photodiagnostic procedure using the inventive azo compounds and their derivatives.
• R 1 and R 2 are independently selected from the group consisting of hydrogen, C1-C10 alkyl, C5-C10 aryl, C1-C10 alkoxyalkyl, C1-C10 polyhydroxyalkyl, -(CH 2 ) a CO 2 H, and -(CH 2 )bNR 3 R 4 ;
• R 3 and R 4 are independently selected from the group consisting of hydrogen, C1-C10 alkyl, C5-C10 aryl, C1-C10 polyhydroxyalkyl, and -(CH 2 ) a CO 2 H;
• R 5 , R 6 , and R 7 are independently selected from the group consisting of hydrogen, C1-C10 alkyl, C5-C10 aryl, hydroxyl, -SO 3 H, C1-C10 alkoxyl, C1-C10 polyhydroxyalkyl, C1-C10 polyalkoxyalkyl, -(CH
• the compound is photoactivated and a phototherapeutic or photodiagnostic procedure for tumors, impaired vasculature or other lesions is subsequently performed.
• a phototherapeutic or photodiagnostic procedure for tumors, impaired vasculature or other lesions is subsequently performed.
• external attachment of an eptiope is used unless the azo compounds themselves preferentially accumulate in the target tissue.
• the photosensitizing chromophore is an anthracycline moiety, it can bind to cancer cells directly and may not require an epitope for targeting purposes.
• Fig. 2 is a schematic pathway for the synthesis of a cyclic azoxanthene derivative.
• Fig. 3 is a schematic pathway for the synthesis of an azoacridine derivative.
• Fig. 4 is a schematic pathway for the synthesis of an azocoumarin derivative. Detailed Description of the Invention
• the present invention discloses novel azo derivatives and their bioconjugates for phototherapy of tumors and other lesions.
• the present invention provides new and structurally diverse compositions comprising organic azo compounds of the general formula 1
• R 1 and R 2 are independently selected from the group consisting of hydrogen, C1-C10 alkyl, C5-C10 aryl, C1-C10 alkoxyalkyl, C1-C10 polyhydroxyalkyl, -(CH 2 ) a C0 2 H, and -(CH 2 ) b NR 3 R 4 ;
• R 3 and R 4 are independently selected from the group consisting of hydrogen, C1-C10 alkyl, C5-C10 aryl, C1-C10 polyhydroxyalkyl, and -(CH 2 ) a CO 2 H;
• R 5 , R 6 , and R 7 are independently selected from the group consisting of hydrogen, C1-C10 alkyl, C5-C10 aryl, hydroxyl, -SO 3 H, C1-C10 alkoxyl, C1-C10 polyhydroxyalkyl, C1-C10 polyalkoxyalkyl, -(CH 2 )
• Ar is an aromatic chromophore that undergoes photosensitization. Aliphatic azo compounds can also be used for phototherapy, but may require high-energy light for activation.
• L is the linker between the chromophore and the epitope.
• Epitope (E) is a particular region of the molecule that is recognized by and binds to the target surface. An epitope is usually, but not always, associated with biomolecules.
• Biomolecules include hormones, amino acids, peptides, peptidomimetics, proteins, nucleosides, nucleotides, nucleic acids, enzymes, carbohydrates, glycomimetics, lipids, albumins, mono- and polyclonal antibodies, receptors, inclusion compounds such as cyclodextrins, and receptor binding molecules.
• biomolecules include steroid hormones for the treatment of breast and prostate lesions; somatostatin, bombesin, CCK, and neurotensin receptor binding molecules for the treatment of neuroendocrine tumors; CCK receptor binding molecules for the treatment of lung cancer; ST receptor and carcinoembryonic antigen (CEA) binding molecules for the treatment of colorectal cancer; dihyroxyindolecarboxylic acid and other melanin producing biosynthetic intermediates for the treatment of melanoma; integrin receptor and atherosclerotic plaque binding molecules for the treatment of vascular diseases; and amyloid plaque binding molecules for the treatment of brain lesions.
• synthetic polymers include polyaminoacids, polyols, polyamines, polyacids, oligonucleotides, aborols, dendrimers, and aptamers.
• Coupling of a photodiagnostic and/or phototherapeutic agent to biomolecules can be accomplished by methods well known in the art, as disclosed in Hnatowich et al., Radiolabeling of Antibodies: A simple and efficient method, Science, 1983, 220, p. 613; Pelegrin et al., Photoimmunodiagnostics with antibody-fluorescein conjugates: in vitro and in vivo preclinical studies. Journal of Cellular Pharmacology. 1992, 3, pp. 141-145; and U.S. Patent No. 5,714,342, each of which is expressly incorporated by reference herein in its entirety.
• receptor-targeted phototherapeutic agents of the present invention should be effective in the treatment of various lesions.
• photoexcitation of the aromatic chromophore effects rapid intramolecular energy transfer to the azo group, resulting in N-C bond rupture with concomitant extrusion of molecular nitrogen and formation of diradicals.
• the diradicals can also combine with each other to form neutral molecules, provided that their spatial orientation is optimal.
• the nitrogen that is released could be in a vibrationally excited state and may cause additional cellular injury. This process is very similar to the process observed with azides.
• an external attachment of an epitope is usually required unless the azo compounds themselves preferentially accumulate in the target tissue, thereby obviating the need for an additional binding group.
• the Ar moiety is an anthracycline moiety, it can bind to cancer cells directly and may not require an epitope for targeting purposes.
• azo compounds The synthesis of azo compounds is accomplished by a variety of methods well known in the art, as disclosed in Sandier and Karo, Azo Compounds, Organic Functional Group Preparations, 1986, Academic Press: New York, pp. 353-409, which is expressly incorporated by reference herein in its entirety.
• the azo derivatives of the invention contain additional functionalities that can be used to attach various types of biomolecules, synthetic polymers, and organized aggregates for selective delivery to various organs or tissues of interest. Preparations of representative compounds from the embodiments are shown in FIGS. 2-4.
• FIG. 2 shows a typical preparation of a cyclic azoxanthene derivative 5.
• Methyl 2-chloro-5-nitrobenzoate 1 is reacted with 3-hydroxybenzyl alcohol 2 and thereafter saponified and cyclized to the nitroxanthone 3.
• the xanthone 3 is then converted to the azo precursor 4 in four standard steps.
• the hydrazino derivative 4 is then oxidized with either mercuric oxide or lead tetraacetate and then conjugated to any desired biomolecule of interest using bifunctional coupling reagents such as phosgene, thiophosgene, carbonyldiimidazole, disuccinimidyl carbonate, and the like.
• the biomolecule of the invention pertains to those binding to colorectal, cervical, ovarian, lung, and neuroendocrine tumors. These include somatostatin, cholesystekinin (CCK), bombesin, neuroendrocrine, and heat sensitive bacterioendotoxin (ST) receptor binding compounds.
• the azoacridine derivative 9 can be prepared in a similar manner to the cyclic azoxanthene derivative whose synthetic scheme is shown in FIG. 2. Methyl 2-chloro-5-nitrobenzoate 1 is reacted with 3-hydroxybenzyl amine 6 and thereafter saponified and cyclized to the nitroacridone 7.
• the acridone 7 is then converted to the azo precursor 8 in four standard steps.
• the hydrazino derivative 8 is then oxidized with either mercuric oxide or lead tetraacetate and then conjugated to a biomolecule, as previously described, using bifunctional coupling reagents such as disuccinimidyl carbonate, disuccinimidyl oxalate, phosgene, thiophosgene, carbonyldiimidazole and the like.
• bifunctional coupling reagents such as disuccinimidyl carbonate, disuccinimidyl oxalate, phosgene, thiophosgene, carbonyldiimidazole and the like.
• FIG. 4 a typical preparation of an azocoumarin derivative 12 is shown.
• the phenol 10 is first alkylated with methyl bromoacetate and then transformed to the azo compound 11 by standard methods.
• the ester 11 is saponified and conjugated
• the biomolecule is selected from the class of tumor markers including, but not limited to, somatostatin, bombesin, neurotensin, CCK, ST, estrogen, and progesterone receptor binding compounds.
• the biomolecule may be selected from the class of integrins, selectins, vascular endothelial growth factor, fibrins, tissue plasminogen activator, thrombin, low density lipoprotein (LDL), high density lipoprotein (HDL), Sialyl Lewis x and its mimics, and atherosclerotic plaque binding compounds.
• a photosensitizer may be delivered to the site of lesion by attaching it to these types of biosynthetic intermediates.
• the method encompasses administering to a patient an effective amount of the compositions of the invention contained in a pharmaceutically acceptable formulation. Thereafter, the photosensitizer is allowed to accumulate in the region of interest, followed by illumination with light of wavelength 300 to 1200 nm, preferably 350 to 850 nm, at the site of the lesion. If the lesion is on the skin surface, it can be directly illuminated; otherwise, endoscopic catheters equipped with a light source may be employed to achieve a phototherapeutic effect. The intensity, power, duration of illumination, and the wavelength of the light may vary widely depending on the location and site of the lesions.
• the fluence rate is preferably, but not always, kept below 200 mW/cm 2 to minimize thermal effects. Appropriate power depends on the size, depth, and pathology of the lesion.
• inventive compositions have broad clinical utility which includes, but is not limited to, phototherapy of tumors, inflammatory processes, and impaired vasculature.
• compositions can be formulated into photodiagnostic or phototherapeutic compositions for enteral (oral or rectal), parenteral, topical, or cutaneous administration.
• Topical or cutaneous delivery of the photosensitizer may also include aerosols, creams, gels, solutions, etc.
• the compositions are administered in doses effective to achieve the desired diagnostic or therapeutic objective. Such doses may vary widely depending upon the particular complex employed, the organs or tissues to be examined, the equipment employed in the clinical procedure, the efficacy of the treatment achieved, and the like.
• These compositions contain an effective amount of the phototherapeutic agent along with conventional pharmaceutical carriers and excipients appropriate for the type of administration contemplated.
• compositions may also include stabilizing agents and skin penetration enhancing agents and also may contain pharmaceutically acceptable buffers, emulsifiers, surfactants, and, optionally, electrolytes such as sodium chloride.
• Formulations for enteral administration may vary widely as is well known in the art. In general, such formulations are liquids, which include an effective amount of the composition in an aqueous solution or suspension. Such enteral compositions may optionally include buffers, surfactants, emulsifiers, thixotropic agents, and the like.
• Compositions for oral administration may also contain flavoring agents and other ingredients for enhancing their organoleptic qualities.
• a topical application can be formulated as a liquid solution, water/oil emulsion, or suspension of particles, depending on the particular nature of the agent and the type of tissue to be targeted. If the azo compound is water soluble, for instance, a solution in water may be applied to or into the target tissue.
• the delivery of the azo compounds into and through the skin may be enhanced by using well known methods and agents such as transdermal permeation enhancers, for example, "azone", N-alkylcyclic amides, dimethylsulfoxide, long-chained aliphatic acids (C10), etc.
• the azo compound may be dissolved in a biocompatible oil (soybean oil, fish oil, vitamin E, linseed oil, vegetable oil, glyceride esters, long-chained fatty esters, etc.) and emulsified with surface-active compounds (vegetable or animal phospholipids; lecithin; long-chained fatty salts and alcohols; Pluronics: polyethylene glycol esters and ethers; etc.) in water to make a topical cream, suspension, water/oil emulsion, water/oil microemulsion, or liposomal suspension to be delivered or applied to the target region.
• a biocompatible oil soybean oil, fish oil, vitamin E, linseed oil, vegetable oil, glyceride esters, long-chained fatty esters, etc.
• surface-active compounds vegetable or animal phospholipids; lecithin; long-chained fatty salts and alcohols; Pluronics: polyethylene glycol
• the dose of the photosensitizer may vary from about 0.1 mg/kg body weight to about 500 mg/kg body weight. In one embodiment, the dose is in the range of about 0.5 to 2 mg/kg body weight.
• a sterile aqueous solution or suspension of the photosensitizer may be present in a concentration ranging from about 1 nM to about 0.5 M, typically in a concentration from about 1 M to about 10 mM.
• a formulated azo compound is administered at a dose or in a concentration which is effective, upon exposure to light, to partially or completely inactivate a target tissue within a biological medium.
• the biological medium is exposed for a period of time to light of a wavelength that is effective to activate the dye which produces type I destruction in the target tissue.
• concentration of the azo compound at the target tissue is the outcome of either passive or active uptake processes in the tissue.
• An example of passive uptake would be where the azo compound is attached or is contained within a particulate carrier. If the carrier is of an appropriate size, in the range of about 100 nm to about 1000 nm, it will "leak" into the perfusion boundary of vascular tumors.
• An example of active uptake would be where a receptor based attachment binds a particular receptor that is expressed on the target tissue.
• the effective concentration of the azo compound is thus dependent on the nature of the formulation, method of delivery, target tissue, activation method and toxicity of the azo to the surrounding normal tissue.
• the following example illustrates a specific embodiment of the invention pertaining to the preparation and properties of a typical bioconjugate derived from bombesin, a bioactive peptide, and a phototherapeutic molecule, the azocoumarin derivative 11b as shown in FIG. 4.
• Example 1 illustrates a specific embodiment of the invention pertaining to the preparation and properties of a typical bioconjugate derived from bombesin, a bioactive peptide, and a phototherapeutic molecule, the azocoumarin derivative 11b as shown in FIG. 4.
• the peptide is prepared by fluorenylmethoxycarbonyl (Fmoc) solid phase peptide synthesis strategy with a commercial peptide synthesizer from Applied Biosystems (Model 432A SYNERGY Peptide Synthesizer).
• the first peptide cartridge containes Wang resin pre-loaded with an amide resin on 25- mole scale.
• the amino acid cartridges are placed on the peptide synthesizer and the product is synthesized from the C- to the N-terminal position.
• Coupling of the Fmoc-protected amino acids (75 mol) to the resin- bound free terminal amine (25 mol) is carried out with 2-(1 H- benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate (HBTU, 75 mol)/N-hydroxybenzotriazole (HOBt, 75 mol).
• HBTU 2-(1 H- benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate
• HOBt N-hydroxybenzotriazole
• Each Fmoc protecting group on the solid support is removed with 20% piperidine in dimethylformamide before a subsequent amino acid is coupled to it.
• the last cartridge contains the azo compound 11b as shown in FIG. 4, which is coupled to the peptide automatically, thus avoiding the need for post- synthetic manipulations.
• the product is cleaved from the solid support with a cleavage mixture containing trifluoroacetic acid
• the peptide- azide conjugate is precipitated with t-butyl methyl ether and lyophilized in water/acetonitrile (2:3) mixture.
• the conjugate is purified by high performance liquid chromatography (HPLC) and analyzed with liquid chromatography/mass spectroscopy (LC/MS).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Biomedical Technology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Biochemistry (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Urology & Nephrology (AREA)
• Gynecology & Obstetrics (AREA)
• Psychiatry (AREA)
• Hospice & Palliative Care (AREA)
• Pregnancy & Childbirth (AREA)
• Endocrinology (AREA)
• Reproductive Health (AREA)
• Vascular Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Radiation-Therapy Devices (AREA)
• Medicinal Preparation (AREA)
• Steroid Compounds (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=25305212

Family Applications (1)

Country Status (5)

Cited By (4)

Families Citing this family (16)

Citations (1)

Family Cites Families (3)

• 2001
  • 2001-05-04 US US09/849,163 patent/US6485704B1/en not_active Expired - Fee Related
• 2002
  • 2002-04-18 EP EP02769275A patent/EP1390080A4/en not_active Withdrawn
  • 2002-04-18 WO PCT/US2002/012217 patent/WO2002089858A1/en not_active Ceased
  • 2002-04-18 JP JP2002586990A patent/JP2005506307A/ja active Pending
  • 2002-04-18 CA CA2445068A patent/CA2445068C/en not_active Expired - Fee Related

Patent Citations (1)

Non-Patent Citations (11)

Also Published As

Similar Documents

Legal Events